{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-303503","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2023-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.437194+00:00","generated_at":"2026-06-07T06:46:29.290013+00:00","sec_items":["1.01","1.02"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Codexis assigns CDX-7108 to Nestlé for $5M upfront plus milestones; closing expected Jan 5","bullets":["Upfront payment of $5M, potential $15M development milestones, $25M commercial milestones, and royalty on net sales above baseline.","Nestlé gets option to buy amylase/protease assets for $2.5M, plus $2.5M milestone payment.","Codexis restricted from developing lipase PERT products for at least three years.","Collaboration and Development Agreements terminated; closing expected Jan 5, 2024.","Company also receives scaled percentage of proceeds from future sale or licensing of CDX-7108 by Nestlé."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-303503","json":"https://secwatch.observer/filing/0001193125-23-303503.json","markdown":"https://secwatch.observer/filing/0001193125-23-303503.md","text":"https://secwatch.observer/filing/0001193125-23-303503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000119312523303503/0001193125-23-303503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000119312523303503/d940896d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:46:29.290013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab9137f99c91ec506cda268d7583a2c123435025","claim":"CODEXIS, INC. terminated Strategic Collaboration Agreement with Nestlé Health Science valued at Termination of Collaboration Agreement and Development Agreement (effective 2023-12-27).","evidence_excerpt":"CDX-7108 was discovered under the Strategic Collaboration Agreement between Nestlé Health Science (“Nestlé”) and the Company, dated October 12, 2017 (“Collaboration Agreement”), and was the subject of a development agreement between Nestle and the Company, dated January 1, 2020 (“Development Agreement”), pursuant to which the parties collaborated to advance the development of CDX-7108.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1200375/000119312523303503/0001193125-23-303503-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Nestlé Health Science"},{"label":"Value","value":"Termination of Collaboration Agreement and Development Agreement"},{"label":"Effective","value":"2023-12-27"}],"fact_type":"material_agreement"},{"claim_id":"b4a2ad0430a8fa611421f205418423257a9904f7","claim":"CODEXIS, INC. entered into A&P Acquisition Agreement with Nestlé Health Science valued at Upfront cash payment of $2.5 million, potential additional $2.5 million payment upon meeting certain (effective 2023-12-27).","evidence_excerpt":"The Company will also grant Nestlé an option to enter into an agreement for the sale of assets related to amylase and protease discovered under the Collaboration Agreement (“A&P Acquisition Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1200375/000119312523303503/0001193125-23-303503-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Nestlé Health Science"},{"label":"Value","value":"Upfront cash payment of $2.5 million, potential additional $2.5 million payment upon meeting certain"},{"label":"Effective","value":"2023-12-27"}],"fact_type":"material_agreement"},{"claim_id":"f85a855fb866402e3c78ea5c5581556143302e6d","claim":"CODEXIS, INC. entered into Acquisition Agreement with Nestlé Health Science valued at Upfront payment of $5.0 million, up to $15.0 million in development milestones and $25.0 million in (effective 2023-12-27).","evidence_excerpt":"On December 27, 2023, the Company and Nestlé entered into an acquisition agreement (the “Acquisition Agreement”), pursuant to which the Company has agreed to assign its interests in CDX-7108 (including associated agreements and intellectual property rights) to Nestlé.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1200375/000119312523303503/0001193125-23-303503-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Nestlé Health Science"},{"label":"Value","value":"Upfront payment of $5.0 million, up to $15.0 million in development milestones and $25.0 million in"},{"label":"Effective","value":"2023-12-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}